Classic and new animal models of Parkinson's disease

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Blesa, Javier ^a,b   Phani, Sudarshan ^a,b   Jackson Lewis, Vernice ^a,b   Przedborski, Serge ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2; OXIDOPAMINE; PARAQUAT; PARKIN; ROTENONE;

CHOLINERGIC NERVE CELL; DOPAMINERGIC NERVE CELL; EXPERIMENTAL MODEL; GENE MUTATION; GENETIC MODEL; HUMAN; LEWY BODY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; REVIEW; STRIATONIGRAL DEGENERATION; ANIMAL; DISEASE MODEL; HAPLORHINI; MOUSE;

ANIMALIA;

ANIMALS; DISEASE MODELS, ANIMAL; HAPLORHINI; MICE; PARKINSON DISEASE;

EID: 84859732716     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/845618     Document Type: Review

References (107)

1. Lees A. J., Hardy J., Revesz T., Parkinson's disease The Lancet 2009 373 9680 2055 2066
2. Spillantini M. G., Schmidt M. L., Lee V. M. Y., Trojanowski J. Q., Jakes R., Goedert M., -synuclein in Lewy bodies [8] Nature 1997 388 6645 839 840
3. Forno L. S., Neuropathology of Parkinson's disease Journal of Neuropathology and Experimental Neurology 1996 55 3 259 272 (Pubitemid 26085575)
4. Braak H., Ghebremedhin E., Rb U., Bratzke H., Del Tredici K., Stages in the development of Parkinson's disease-related pathology Cell and Tissue Research 2004 318 1 121 134 (Pubitemid 39362633)
5. Chaudhuri K. R., Healy D. G., Schapira A. H. V., Non-motor symptoms of Parkinson's disease: diagnosis and management Lancet Neurology 2006 5 3 235 245 (Pubitemid 43238347)
6. Dauer W., Przedborski S., Parkinson's disease: mechanisms and models Neuron 2003 39 6 889 909 (Pubitemid 37130207)
7. Carlsson A., Lindqvist M., Magnusson T., 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists Nature 1957 180 4596 1200
8. Carlsson A., The occurrence, distribution and physiological role of catecholamines in the nervous system Pharmacological reviews 1959 11 2 490 493
9. Betarbet R., Sherer T. B., Timothy Greenamyre J., Animal models of Parkinson's disease BioEssays 2002 24 4 308 318 (Pubitemid 34305686)
10. Dawson T. M., Ko H. S., Dawson V. L., Genetic Animal Models of Parkinson's Disease Neuron 2010 66 5 646 661
11. Schwarting R. K. W., Huston J. P., Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae Progress in Neurobiology 1996 49 3 215 266 (Pubitemid 26276331)
12. Schwarting R. K. W., Huston J. P., The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments Progress in Neurobiology 1996 50 2-3 275 331 (Pubitemid 26412599)
13. Schwarting R. K. W., Huston J. P., Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions NeuroToxicology 1997 18 3 689 708 (Pubitemid 27430298)
14. Senoh S., Witkop B., Non-enzymatic conversions of dopamine to norepinephrine and trihydroxyphenethylamines Journal of the American Chemical Society 1959 81 23 6222 6231
15. Ungerstedt U., 6-hydroxy-dopamine induced degeneration of central monoamine neurons European Journal of Pharmacology 1968 5 1 107 110
16. Roeling T. A. P., Docter G. J., Voorn P., Melchers B. P. C., Wolters E. C., Groenewegen H. J., Effects of unilateral 6-hydroxydopamine lesions on neuropeptide immunoreactivity in the basal ganglia of the common marmoset, Callithrix jacchus, a quantitative immunohistochemical analysis Journal of Chemical Neuroanatomy 1995 9 3 155 164
17. Valette H., Deleuze P., Syrota A., Delforge J., Crouzel C., Fuseau C., Loisance D., Canine myocardial beta-adrenergic, muscarinic receptor densities after denervation: a PET study Journal of Nuclear Medicine 1995 36 1 140 146
18. Annett L. E., Torres E. M., Clarke D. J., Ishida Y., Barker R. A., Ridley R. M., Baker H. F., Dunnett S. B., Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age Cell Transplantation 1997 6 6 557 569 (Pubitemid 28013618)
19. Ruffy R., Leonard M., Chemical cardiac sympathetic denervation hampers defibrillation in the dog Journal of Cardiovascular Electrophysiology 1997 8 1 62 67 (Pubitemid 27081710)
20. Sachs C., Jonsson G., Mechanisms of action of 6-hydroxydopamine Biochemical Pharmacology 1975 24 1 1 8
21. Martin G. E., Myers R. D., Newberg D. C., Catecholamine release by intracerebral perfusion of 6 hydroxydopamine and desipramine European Journal of Pharmacology 1976 36 2 299 311
22. Perese D. A., Ulman J., Viola J., Ewing S. E., Bankiewicz K. S., A 6-hydroxydopamine-induced selective parkinsonian rat model Brain Research 1989 494 2 285 293 (Pubitemid 19194542)
23. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D. M., Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine Neuroscience 1995 67 3 631 647
24. Cohen G., Oxy-radical toxicity in catecholamine neurons NeuroToxicology 1984 5 1 77 82 (Pubitemid 14108953)
25. Blandini F., Armentero M. T., Martignoni E., The 6-hydroxydopamine model: news from the past Parkinsonism and Related Disorders 2008 14 2 S124 S129
26. Sauer H., Oertel W. H., Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat Neuroscience 1994 59 2 401 415 (Pubitemid 24098798)
27. Lee C. S., Sauer H., Bjrklund A., Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat Neuroscience 1996 72 3 641 653 (Pubitemid 26124689)
28. Ungerstedt U., Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system Acta Physiologica Scandinavica, Supplement 1971 367 95 122
29. Bourn W. M., Chin L., Picchioni A. L., Enhancement of audiogenic seizure by 6-hydroxydopamine Journal of Pharmacy and Pharmacology 1972 24 11 913 914
30. Knoll J., The pharmacology of (-)deprenyl Journal of Neural Transmission. Supplementum 1986 22 75 89
31. Graham J. D., Lewis M. J., Williams J., Proceedings: The effect of delta-1-tetrahydrocannabinol on the noradrenaline and dopamine content of the brain and heart of the rat British Journal of Pharmacology 1974 52 3 446
32. Langston J. W., Ballard P., Tetrud J. W., Irwin I., Chronic parkinsonism in humans due to a product of meperidine-analog synthesis Science 1983 219 4587 979 980 (Pubitemid 13189531)
33. Forno L. S., DeLanney L. E., Irwin I., Langston J. W., Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations Advances in neurology 1993 60 600 608
34. Halliday G., Herrero M. T., Murphy K., McCann H., Ros-Bernal F., Barcia C., Mori H., Blesa F. J., Obeso J. A., No Lewy pathology in monkeys with over 10 years of severe MPTP parkinsonism Movement Disorders 2009 24 10 1519 1523
35. Kowall N. W., Hantraye P., Brouillet E., Beal M. F., McKee A. C., Ferrante R. J., MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons NeuroReport 2000 11 1 211 213 (Pubitemid 30053420)
36. Fornai F., Schlter O. M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C. L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., Sdhof T. C., Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and -synuclein Proceedings of the National Academy of Sciences of the United States of America 2005 102 9 3413 3418 (Pubitemid 40328059)
37. Cui M., Aras R., Christian W. V., Rappold P. M., Hatwar M., Panza J., Jackson-Lewis V., Javitch J. A., Ballatori N., Przedborski S., Tieu K., The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway Proceedings of the National Academy of Sciences of the United States of America 2009 106 19 8043 8048
38. Javitch J. A., D'Amato R. J., Strittmatter S. M., Snyder S. H., Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity Proceedings of the National Academy of Sciences of the United States of America 1985 82 7 2173 2177 (Pubitemid 15056491)
39. Bezard E., Gross C. E., Fournier M. C., Dovero S., Bloch B., Jaber M., Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter Experimental Neurology 1999 155 2 268 273 (Pubitemid 29124720)
40. Gainetdinov R. R., Fumagalli F., Wang Y. M., Jones S. R., Levey A. I., Miller G. W., Caron M. G., Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice Journal of Neurochemistry 1998 70 5 1973 1978 (Pubitemid 28207819)
41. Guillot T. S., Shepherd K. R., Richardson J. R., Wang M. Z., Li Y., Emson P. C., Miller G. W., Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis Journal of Neurochemistry 2008 106 5 2205 2217
42. Guillot T. S., Miller G. W., Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons Molecular Neurobiology 2009 39 2 149 170
43. Burke W. J., Kumar V. B., Pandey N., Panneton W. M., Gan Q., Franko M. W., O'Dell M., Li S. W., Pan Y., Chung H. D., Galvin J. E., Aggregation of -synuclein by DOPAL, the monoamine oxidase metabolite of dopamine Acta Neuropathologica 2008 115 2 193 203
44. Panneton W. M., Kumar V. B., Gan Q., Burke W. J., Galvin J. E., The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis PLoS One 2010 5 12
45. Zigmond M. J., Berger T. W., Grace A. A., Stricker E. M., Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism Molecular and Chemical Neuropathology 1989 10 3 185 200 (Pubitemid 19204706)
46. Chiueh C. C., Markey S. P., Burns R. S., Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in the rat European Journal of Pharmacology 1984 100 2 189 194 (Pubitemid 14138269)
47. Przedborski S., Jackson-Lewis V., Naini A. B., Jakowec M., Petzinger G., Miller R., Akram M., The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): a technical review of its utility and safety Journal of Neurochemistry 2001 76 5 1265 1274 (Pubitemid 32198231)
48. Langston J. W., Langston E. B., Irwin I., MPTP-induced parkinsonism in human and non-human primatesclinical and experimental aspects Acta Neurologica Scandinavica 1984 70 supplement 100 49 54 (Pubitemid 14060412)
49. Bankiewicz K. S., Oldfield E. H., Chiueh C. C., Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Life Sciences 1986 39 1 7 16 (Pubitemid 16090932)
50. Iravani M. M., Syed E., Jackson M. J., Johnston L. C., Smith L. A., Jenner P., A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets European Journal of Neuroscience 2005 21 4 841 854 (Pubitemid 40461038)
51. Hantraye P., Varastet M., Peschanski M., Riche D., Cesaro P., Willer J. C., Maziere M., Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons Neuroscience 1993 53 1 169 178 (Pubitemid 23083318)
52. Bezard E., Imbert C., Deloire X., Bioulac B., Gross C. E., A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey Brain Research 1997 766 1-2 107 112 (Pubitemid 27431440)
53. Mounayar S., Boulet S., Tandé D., Jan C., Pessiglione M., Hirsch E. C., Féger J., Savasta M., Franois C., Tremblay L., A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery Brain 2007 130 11 2898 2914 (Pubitemid 350033961)
54. Blesa J., Juri C., Collantes M., Peuelas I., Prieto E., Iglesias E., Mart-Climent J., Arbizu J., Zubieta J. L., Rodrguez-Oroz M. C., Garca-Garca D., Richter J. A., Cavada C., Obeso J. A., Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An 18F-DOPA and 11C-DTBZ PET study Neurobiology of Disease 2010 38 3 456 463
55. Ovadia A., Zhang Z., Gash D. M., Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys Neurobiology of Aging 1995 16 6 931 937 (Pubitemid 26019086)
56. Pessiglione M., Guehl D., Hirsch E. C., Féger J., Tremblay L., Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism. I. Effects of task complexity European Journal of Neuroscience 2004 19 2 426 436 (Pubitemid 38177881)
57. Schneider JS, Modeling Cognitive Deficits Associated with Parkinsonism in the Chronic-Low-Dose MPTP-Treated Monkey 2006 Boca Raton, Fla, USA CRC Press
58. Anderson G., Noorian A. R., Taylor G., Anitha M., Bernhard D., Srinivasan S., Greene J. G., Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease Experimental Neurology 2007 207 1 4 12 (Pubitemid 47332479)
59. Fox S. H., Chuang R., Brotchie J. M., Serotonin and Parkinson's disease: on movement, mood, and madness Movement Disorders 2009 24 9 1255 1266
60. Barraud Q., Obeid I., Aubert I., Barrire G., Contamin H., McGuire S., Ravenscroft P., Porras G., Tison F., Bezard E., Ghorayeb I., Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate PLoS One 2010 5 10
61. Vezoli J., Fifel K., Leviel V., Dehay C., Kennedy H., Cooper H. M., Gronfier C., Procyk E., Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson's disease PLoS One 2011 6 8
62. Bergman H., Wichmann T., DeLong M. R., Reversal of experimental Parkinsonism by lesions of the subthalamic nucleus Science 1990 249 4975 1436 1438
63. Guridi J., Herrero M. T., Luquin M. R., Guillén J., Ruberg M., Laguna J., Vila M., Javoy-Agid F., Agid Y., Hirsch E., Obeso J. A., Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis Brain 1996 119 5 1717 1727 (Pubitemid 26376797)
64. Bezard E., Przedborski S., A tale on animal models of Parkinson's Disease Movement Disorders 2011 26 6 993 1002
65. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S. J., Przedborski S., Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease Proceedings of the National Academy of Sciences of the United States of America 2001 98 5 2837 2842 (Pubitemid 32209570)
66. Dauer W., Kholodilov N., Vila M., Trillat A. C., Goodchild R., Larsen K. E., Staal R., Tieu K., Schmitz Y., Yuan C. A., Rocha M., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R., Hen R., Resistance of -synuclein null mice to the parkinsonian neurotoxin MPTP Proceedings of the National Academy of Sciences of the United States of America 2002 99 22 14524 14529 (Pubitemid 35257704)
67. Berry C., La Vecchia C., Nicotera P., Paraquat and parkinson's disease Cell Death and Differentiation 2010 17 7 1115 1125
68. Day B. J., Patel M., Calavetta L., Chang L. Y., Stamler J. S., A mechanism of paraquat toxicity involving nitric oxide synthase Proceedings of the National Academy of Sciences of the United States of America 1999 96 22 12760 12765 (Pubitemid 29513576)
69. Przedborski S., Ischiropoulos H., Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease Antioxidants and Redox Signaling 2005 7 5-6 685 693 (Pubitemid 40563207)
70. Brooks A. I., Chadwick C. A., Gelbard H. A., Cory-Slechta D. A., Federoff H. J., Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss Brain Research 1999 823 1-2 1 10 (Pubitemid 29225488)
71. McCormack A. L., Thiruchelvam M., Manning-Bog A. B., Thiffault C., Langston J. W., Cory-Slechta D. A., Di Monte D. A., Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat Neurobiology of Disease 2002 10 2 119 127 (Pubitemid 34775465)
72. Thiffault C., Langston J. W., Di Monte D. A., Increased striatal dopamine turnover following acute administration of rotenone to mice Brain Research 2000 885 2 283 288
73. Thiruchelvam M., Brockel B. J., Richfield E. K., Baggs R. B., Cory-Slechta D. A., Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Research 2000 873 2 225 234 (Pubitemid 30619046)
74. Rappold P. M., Cui M., Chesser A. S., Tibbett J., Grima J. C., Duan L., Sen N., Javitch J. A., Tieua K., Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3 Proceedings of the National Academy of Sciences of the United States of America 2011 108 51 20766 20771
75. Manning-Bog A. B., McCormack A. L., Li J., Uversky V. N., Fink A. L., Di Monte D. A., The herbicide paraquat causes up-regulation and aggregation of -synuclein in mice: paraquat and -synuclein Journal of Biological Chemistry 2002 277 3 1641 1644 (Pubitemid 34968732)
76. Takahashi R. N., Rogerio R., Zanin M., Maneb enhances MPTP neurotoxicity in mice Research Communications in Chemical Pathology and Pharmacology 1989 66 1 167 170 (Pubitemid 19267344)
77. Kachroo A., Irizarry M. C., Schwarzschild M. A., Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration Experimental Neurology 2010 223 2 657 661
78. Butterfield P. G., Valanis B. G., Spencer P. S., Lindeman C. A., Nutt J. G., Environmental antecedents of young-onset Parkinson's disease Neurology 1993 43 6 1150 1158 (Pubitemid 23177715)
79. Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L., Richardson R. J., The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living Neurology 1998 50 5 1346 1350 (Pubitemid 28240350)
80. Barlow B. K., Richfield E. K., Cory-Slechta D. A., Thiruchelvam M., A fetal risk factor for Parkinson's disease Developmental Neuroscience 2004 26 1 11 23 (Pubitemid 39451878)
81. Tang C. C., Poston K. L., Dhawan V., Eidelberg D., Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease Journal of Neuroscience 2010 30 3 1049 1056
82. Tanner C. M., Kame F., Ross G. W., Hoppin J. A., Goldman S. M., Korell M., Marras C., Bhudhikanok G. S., Kasten M., Chade A. R., Comyns K., Richards M. B., Meng C., Priestley B., Fernandez H. H., Cambi F., Umbach D. M., Blair A., Sandler D. P., Langston J. W., Rotenone, paraquat, and Parkinson's disease Environmental Health Perspectives 2011 119 6 866 872
83. Hisata J., Lake and stream rehabilitation: rotenone use and health risks. Final supplemental environmental impact statement 2002 Washington Satet Deparment of Fish and Wildlife
84. Inden M., Kitamura Y., Takeuchi H., Yanagida T., Takata K., Kobayashi Y., Taniguchi T., Yoshimoto K., Kaneko M., Okuma Y., Taira T., Ariga H., Shimohama S., Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone Journal of Neurochemistry 2007 101 6 1491 1504 (Pubitemid 46848844)
85. Inden M., Kitamura Y., Abe M., Tamaki A., Takata K., Taniguchi T., Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice Biological and Pharmaceutical Bulletin 2011 34 1 92 96
86. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V., Greenamyre J. T., Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nature Neuroscience 2000 3 12 1301 1306
87. Alam M., Mayerhofer A., Schmidt W. J., The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA Behavioural Brain Research 2004 151 1-2 117 124 (Pubitemid 38501434)
88. Cannon J. R., Tapias V., Na H. M., Honick A. S., Drolet R. E., Greenamyre J. T., A highly reproducible rotenone model of Parkinson's disease Neurobiology of Disease 2009 34 2 279 290
89. Hglinger G. U., Féger J., Prigent A., Michel P. P., Parain K., Champy P., Ruberg M., Oertel W. H., Hirsch E. C., Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats Journal of Neurochemistry 2003 84 3 491 502 (Pubitemid 36182248)
90. Sherer T. B., Kim J. H., Betarbet R., Greenamyre J. T., Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and -synuclein aggregation Experimental Neurology 2003 179 1 9 16 (Pubitemid 36062614)
91. Wu Y.-N., Johnson S. W., Dopamine oxidation facilitates rotenone-dependent potentiation of N-methyl-d-aspartate currents in rat substantia nigra dopamine neurons Neuroscience 2011 195 138 144
92. Ferrante R. J., Schulz J. B., Kowall N. W., Beal M. F., Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra Brain Research 1997 753 1 157 162 (Pubitemid 27156146)
93. Takeuchi H., Yanagida T., Inden M., Takata K., Kitamura Y., Yamakawa K., Sewada H., Izumi Y., Yamamoto N., Kihara T., Uemura K., Inoue H., Taniguchi T., Akaike A., Takahashi R., Shimohama S., Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models Journal of Neuroscience Research 2009 87 2 576 585
94. Pan-Montojo F., Anichtchik O., Dening Y., Knels L., Pursche S., Jung R., Jackson S., Gille G., Spillantini M. G., Reichmann H., Funk R. H. W., Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice PLoS One 2010 5 1
95. Pan-Montojo F. J., Funk R. H. W., Oral administration of rotenone using a gavage and image analysis of alpha-synuclein inclusions in the enteric nervous system Journal of Visualized Experiments 2010 44
96. Krger R., Kuhn W., Mller T., Woitalla D., Graeber M., Ksel S., Przuntek H., Epplen J. T., Schls L., Riess O., Ala30Pro mutation in the gene encoding -synuclein in Parkinson's disease Nature Genetics 1998 18 2 106 108
97. Giasson B. I., Duda J. E., Quinn S. M., Zhang B., Trojanowski J. Q., Lee V. M. Y., Neuronal -synucleinopathy with severe movement disorder in mice expressing A53T human -synuclein Neuron 2002 34 4 521 533 (Pubitemid 34628750)
98. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L., Dopaminergic loss and inclusion body formation in -synuclein mice: Implications for neurodegenerative disorders Science 2000 287 5456 1265 1269 (Pubitemid 30112148)
99. Abeliovich A., Schmitz Y., Farias I., Choi-Lundberg D., Ho W. H., Castillo P. E., Shinsky N., Garcia Verdugo J. M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., Rosenthal A., Mice lacking -synuclein display functional deficits in the nigrostriatal dopamine system Neuron 2000 25 1 239 252 (Pubitemid 30316525)
100. Thomas B., Mandir A. S., West N., Liu Y., Andrabi S. A., Stirling W., Dawson V. L., Dawson T. M., Lee M. K., Resistance to MPTP-Neurotoxicity in -synuclein knockout mice is complemented by human -synuclein and associated with increased -synuclein and Akt activation PLoS One 2011 6 1
101. Feany M. B., Bender W. W., A Drosophila model of Parkinson's disease Nature 2000 404 6776 394 398 (Pubitemid 30164341)
102. Wang D., Tang B., Zhao G., Pan Q., Xia K., Bodmer R., Zhang Z., Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons Molecular Neurodegeneration 2008 3 1, article no. 3
103. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R. J., Calne D. B., Stoessl A. J., Pfeiffer R. F., Patenge N., Carbajal I. C., Vieregge P., Asmus F., Mller-Myhsok B., Dickson D. W., Meitinger T., Strom T. M., Wszolek Z. K., Gasser T., Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology Neuron 2004 44 4 601 607 (Pubitemid 39531225)
104. Li Y., Liu W., Oo T. F., Wang L., Tang Y., Jackson-Lewis V., Zhou C., Geghman K., Bogdanov M., Przedborski S., Beal M. F., Burke R. E., Li C., Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease Nature Neuroscience 2009 12 7 826 828
105. Moore D. J., Dawson T. M., Value of genetic models in understanding the cause and mechanisms of Parkinson's disease Current Neurology and Neuroscience Reports 2008 8 4 288 296
106. Shin J.-H., Ko H. S., Kang H., Lee Y., Lee Y. -I., Pletinkova O., Troconso J. C., Dawson V. L., Dawson T. M., PARIS (ZNF746) repression of PGC-1 contributes to neurodegeneration in parkinson's disease Cell 2011 144 5 689 702
107. Peng J., Oo M. L., Andersen J. K., Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration Journal of Neurochemistry 2010 115 6 1363 1373